Introduction
TargetFlame, immune dysfunction, schizophrenia spectrum disorders, psychiatric, schizophrenia
INFLAMMATION
Despite the significant social and healthcare burden caused by difficult therapy of schizophrenia, no novel antipsychotic concepts have been established in psychiatric care for more than 20 years. In the past 2 years new concepts (such as trace amine-associated receptor 1 (TAAR1) (Koblan et al. There is ample evidence that immune dysfunction, and more specifically inflammation, is associated in a subgroup with schizophrenia (Muller In this context, the effects of add-on Celecoxib treatment in patients with schizophrenia spectrum disorders and inflammatory cytokine profile trial (TargetFlame) is the first clinical study aimed at evaluating the efficacy, safety and cost-effectiveness of the antiphlogistic agent Celecoxib added to an ongoing antipsychotic treatment in a subset of schizophrenia patients exhibiting an inflammatory profile. Inflamed patients will be identified using an unsupervised classification method based on serum levels of the three pro-inflammatory cytokines IL-6, IL-1-beta and TNF-alpha established by a member of our study group. Thus, TargetFlame combines a drug repurposing and a precision medicine approach.